An investigator proposes to study a marketed product sold to treat high blood pressure in individuals over age 12 using a liquid formulation for children under age 12. the drug sponsor hopes that the information from the research can be used to change the labeling for younger children to be able to use the drug. which of the following is the investigator's most appropriate course of action?